Korro to Present at the TD Cowen 45th Annual Health Care Conference
Korro Bio (Nasdaq: KRRO), a clinical-stage biopharmaceutical company specializing in RNA-based genetic medicines, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The event will take place on March 4, 2025, at the Boston Marriott Copley Place.
CEO and President Ram Aiyar, Ph.D. will deliver a presentation at 11:50 a.m. ET, while COO Todd Chappell will engage in one-on-one investor meetings during the conference. Interested parties can access a live webcast of the presentation through Korro's website investor section, with a replay available for 30 days post-event.
Korro Bio (Nasdaq: KRRO), un'azienda biofarmaceutica in fase clinica specializzata in medicinali genetici basati su RNA, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. L'evento si svolgerà il 4 marzo 2025, presso il Boston Marriott Copley Place.
Il CEO e Presidente Ram Aiyar, Ph.D. presenterà un intervento alle 11:50 ET, mentre il COO Todd Chappell parteciperà a incontri individuali con gli investitori durante la conferenza. Le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso la sezione investitori del sito web di Korro, con una registrazione disponibile per 30 giorni dopo l'evento.
Korro Bio (Nasdaq: KRRO), una empresa biofarmacéutica en etapa clínica especializada en medicamentos genéticos basados en ARN, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. El evento se llevará a cabo el 4 de marzo de 2025, en el Boston Marriott Copley Place.
El CEO y Presidente Ram Aiyar, Ph.D. realizará una presentación a las 11:50 a.m. ET, mientras que el COO Todd Chappell se reunirá individualmente con inversores durante la conferencia. Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de inversores del sitio web de Korro, con una repetición disponible durante 30 días después del evento.
Korro Bio (Nasdaq: KRRO)는 RNA 기반 유전자 의약품을 전문으로 하는 임상 단계의 생명공학 회사로, TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2025년 3월 4일 보스턴 메리어트 코플리 플레이스에서 열릴 예정입니다.
CEO이자 사장인 Ram Aiyar, Ph.D.는 동부 표준시 기준 오전 11시 50분에 발표를 진행하며, COO인 Todd Chappell은 컨퍼런스 기간 동안 투자자와의 일대일 미팅에 참여할 것입니다. 관심 있는 분들은 Korro 웹사이트의 투자자 섹션을 통해 발표의 라이브 웹캐스트에 접근할 수 있으며, 이벤트 후 30일 동안 재생이 가능합니다.
Korro Bio (Nasdaq: KRRO), une entreprise biopharmaceutique en phase clinique spécialisée dans les médicaments génétiques basés sur l'ARN, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. L'événement se déroulera le 4 mars 2025, au Boston Marriott Copley Place.
Le PDG et Président Ram Aiyar, Ph.D. fera une présentation à 11h50 ET, tandis que le COO Todd Chappell participera à des réunions individuelles avec des investisseurs pendant la conférence. Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section investisseurs du site web de Korro, avec un replay disponible pendant 30 jours après l'événement.
Korro Bio (Nasdaq: KRRO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf RNA-basierte Gentherapien spezialisiert hat, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Die Veranstaltung findet am 4. März 2025 im Boston Marriott Copley Place statt.
CEO und Präsident Ram Aiyar, Ph.D. wird um 11:50 Uhr ET eine Präsentation halten, während COO Todd Chappell während der Konferenz Einzelgespräche mit Investoren führen wird. Interessierte können über den Investorenbereich der Korro-Website auf einen Live-Stream der Präsentation zugreifen, mit einer Wiederholung, die 30 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. ET at the Boston Marriott Copley Place. Todd Chappell, Chief Operating Officer, will also participate in 1x1 investor meetings at the conference.
A live webcast of the presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days.
About Korro
Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investor & Media Contact
Tim Palmer
IR@korrobio.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Korro Bio (KRRO) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch Korro Bio's (KRRO) TD Cowen conference presentation?
What type of genetic medicines is Korro Bio (KRRO) developing?
Who will represent Korro Bio (KRRO) at the TD Cowen Healthcare Conference?
